The effect of two BRAF inhibitors, namely vemurafenib and dabrafenib, on cell proliferation was evaluated using the established BRAFV600E-expressing TCC-NECT-2 cell line and two human cancer cell lines including BRAFV600E-harboring HT29 colorectal cancer cells and BRAFWT-expressing Sui73 pancreatic cancer cells, which harbor a KRAS mutation (183A>C). The gene discussed is KRAS; the disease is familial pancreatic carcinoma.